Evidence map›Paper›PMID 37761329›Full record

ArticleDiagnostics (Basel, Switzerland)2023

The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking.

Aikaterini Tsantikidi, Eirini Papadopoulou, Vasiliki Metaxa-Mariatou, George Kapetsis, Georgios Tsaousis, Angeliki Meintani, Chrysiida Florou-Chatzigiannidou, Maria Gazouli, Christos Papadimitriou, Eleni Timotheadou and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer.International journal of molecular sciences · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. NGS coverage accurately predictsFrontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Aikaterini TsantikidiGenekor Medical S.A., 15344 Athens, Greece.
Eirini PapadopoulouGenekor Medical S.A., 15344 Athens, Greece.
Vasiliki Metaxa-MariatouGenekor Medical S.A., 15344 Athens, Greece.
George KapetsisGenekor Medical S.A., 15344 Athens, Greece.ORCID 0000-0002-6608-3406
Georgios TsaousisGenekor Medical S.A., 15344 Athens, Greece.ORCID 0000-0002-8975-8779
Angeliki MeintaniGenekor Medical S.A., 15344 Athens, Greece.
Chrysiida Florou-ChatzigiannidouGenekor Medical S.A., 15344 Athens, Greece.
Maria GazouliDepartment of Basic Medical Sciences, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-3295-6811
Christos PapadimitriouSecond Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-8084-0445
Eleni TimotheadouDepartment of Medical Oncology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, 56429 Thessaloniki, Greece.ORCID 0000-0003-2545-8926
Athanasios KotsakisOncology Department, University General Hospital of Larissa, 41334 Larissa, Greece.ORCID 0000-0002-5530-6774
Anastasios BoutisFirst Department of Clinical Oncology, Theagenio Hospital, 54639 Thessaloniki, Greece.ORCID 0000-0002-5660-3025
Ioannis BoukovinasOncology Department, Bioclinic of Thessaloniki, 54622 Thessaloniki, Greece.
Eleftherios KampletsasDepartment of Medical, Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece.
Loukas KontovinisOncology Department, "Euromedica" General Clinic, 54645 Thessaloniki, Greece.
Elena FountzilasSecond Department of Medical Oncology, Euromedica General Clinic, 54645 Thessaloniki, Greece.
Charalampos AndreadisSecond Department of Clinical Oncology, Theagenio Hospital, 54639 Thessaloniki, Greece.
Charisios KaranikiotisDepartment of Medical Oncology, 424 Army General Hospital, 56429 Thessaloniki, Greece.
Dimitrios FilippouDepartment of Anatomy, Faculty of Health Sciences, Medical School, National and Kapodistrian University of Athens, 15772 Athens, Greece.
Georgios TheodoropoulosDepartment of Surgery, National and Kapodistrian University of Athens, Hippocration General Hospital, 15772 Athens, Greece.
Mustafa ÖzdoğanDivision of Medical Oncology, Memorial Hospital, Antalya 07025, Turkey.
George NasioulasSecond Department of Medical Oncology, Euromedica General Clinic, 54645 Thessaloniki, Greece.
Athens Medical Center · GRNational and Kapodistrian University of Athens · GREuromedica · GRTheageneio General Hospital · GR424 General Military Hospital · GRAristotle University of Thessaloniki · GRUniversity Hospital of Ioannina · GRUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several tumor types have been efficiently treated with PARP inhibitors (PARPis), which are now approved for the treatment of ovarian, breast, prostate, and pancreatic cancers. The

Indexed as

biomarkersDNA repairhomologous recombination deficiencyloss of heterozygositypoly (ADP-ribose) polymerase (PARP) inhibitorsprecision oncology

Identifiers

PMID37761329
PMCPMC10529941
OpenAlexW4386838378

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.